PMC:7111504 / 2085-2359
Annnotations
LitCovid-PubTator
| Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
|---|---|---|---|---|---|
| 39 | 256-264 | Disease | denotes | infected | MESH:D007239 |
LitCovid-PD-CLO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T30 | 3-9 | http://purl.obolibrary.org/obo/UBERON_0001456 | denotes | facing |
| T31 | 10-11 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T32 | 41-42 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T33 | 71-72 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
| T34 | 92-93 | http://purl.obolibrary.org/obo/CLO_0001020 | denotes | a |
LitCovid-sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T21 | 0-274 | Sentence | denotes | In facing a rapid epidemical outbreak to a novel and unknown pathogen, a key bottleneck for a proper and deep investigation, which is fundamental for vaccine development, is the limited -- to almost no -- access of the scientific community to samples from infected subjects. |